Table 2 Relative contraindications as defined by national guidelines
Female | Male | p-value | |
|---|---|---|---|
Uncontrolled hypertension | 29 (13.1) | 18 (8.0) | 0.08 |
Fever or active infection | 0 (0.0) | 1 (1.47) | 0.5 |
Malignant or terminal disease | 11 (5.5) | 4 (2.2) | 0.12 |
Risk of bleeding | 23 (14.7) | 26 (17.3) | 0.54 |
Ongoing bleeding | 5 (2.0) | 9 (3.6) | 0.42 |
Moderate/severe heart failure | 8 (3.2) | 5 (2.0) | 0.6 |
Previous allergy to contrast | 0(0.0) | 0(0.0) | NA |
Digoxin intoxication | 0 (0.0) | 0 (0.0) | NA |
Electrolyte-disturbances (4.6 mM < potassium level < 3.5 mM) | 49 (24.6) | 29 (15.8) | 0.031 |
At least one of the above mentioned relative contraindication (excluding heart failure) | 130 (52.0) | 120 (48.0) | 0.060 |